CureDuchenne Webinar: NS Pharma Announcement of Viltepso

NS Pharma Announcement of Viltepso: A New FDA-Approved Treatment for Patients With Duchenne Muscular Dystrophy (DMD) Amenable to Exon 53 Skipping

View this webinar to learn more about Viltepso from Anna Parievsky, PhD, NS Pharma’s Medical Science Liaison, and its associated patient support program from Jonathan Cabral, NS Pharma’s US Head of Patient Services

You’ll be prompted to enter your name and email address to view the recording.